



Alaska Medical Assistance DUR Committee Meeting
Friday, November 18th, 2016
Frontier Building, 3601 C Street; Room 880/890
1:00pm
1.800.315.6338, access code 24251#

Agenda

- (1) Review of minutes from January (correction) and April 2016
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
- (4) Annual review of DUR Committee Bylaws
- (5) Pharmacy Program Strategic Initiatives SFY2017 - Pharmacy Director
- (6) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - b. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. Periodic Review
 1. Hepatitis C Direct Acting Antivirals
 2. Botulinum Toxin
 3. Hereditary Angioedema (Cinryze, Berinert, Firazyr)
 - c. Proposed New Prior Authorization, Quantity Limits, Edits
 1. Hereditary Angioedema (Ruconest, Kalbitor)
 2. Iron Chelators
 3. Hemangeol
 4. Qbrelis
 5. Acne agents
 6. Topical Tretinoin
 7. Hemophilia
- <<Break>>
- (7) Past Intervention Informational Updates
 - a. Oxycodone Liquid provider letters
- (8) FDA/DEA Updates
 - a. FDA Drug Safety Communications
 - i. Hepatitis B reactivation with Hepatitis C DAA treatment [10/4/2016]
 - ii. Risks when combining opioids with benzodiazepines [8/31/2016]
 - iii. Updated warnings for fluoroquinolones [7/26/2016, 5/12/2016]
 - iv. Kidney warnings for canagliflozin and dapagliflozin [6/14/2016]
 - v. Off-label use of ketoconazole tablets and risk of death [5/19/2016]
 - vi. Increased risk of amputations with canagliflozin [5/18/2016]
 - vii. Risk of skin reactions with olanzapine [5/10/2016]
 - viii. Impulse-control problems with aripiprazole [5/3/2016]
 - ix. Brintellix name change [5/2/2016]
 - x. Use of fluconazole in pregnancy [4/26/2016]
- (9) FAERS Reports
- (10) Quality Measures
- (11) Trend Report
- (12) End of Public Meeting